Globe on Big Pharma R&D Failure
3 Comments
Recent Posts
The Law Bytes Podcast, Episode 248: Mark Surman on Why Canada’s AI Strategy Should Prioritize Public AI Models 
We Need More Canada in the Training Data: My Appearance Before the Standing Committee on Canadian Heritage on AI and the Creative Sector 
The Law Bytes Podcast, Episode 247: My Senate Appearance on the Bill That Could Lead to Canada-Wide Blocking of X, Reddit and ChatGPT 
The Law Bytes Podcast, Episode 246: Mohamed Zohiri on the Rise and Emerging Regulation of Stablecoins 
Senate Bill Would Grant Government Regulatory Power to Mandate Age Verification For Search, Social Media and AI Services Accompanied By Threat of Court Ordered Blocking of Lawful Content
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?